Allergy Therapeutics plc provided earnings guidance for the six months ended December 31, 2018. For the period, the company expects revenue to be £46.7 million. representing 10.6% growth on both a reported and constant currency basis. In terms of geography, the main contributors to this strong sales growth are Germany, Austria, Switzerland and Netherlands. Spain has continued to grow well despite the withdrawal of all bacterial products across the market. In terms of product mix, this growth is being driven primarily by the Group's ultra-short course, aluminium-free treatments (Pollinex and Pollinex Quattro) as well as Acarovac and Venomil. The Group continues to gain market share in Germany and again achieved number one position in this market for the month of October 2018 (the Group's busiest month of the year) for the second year running.